Inovio Pharmaceuticals, Inc.
INO
$1.68
$0.053.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 65.30K | 117.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 65.30K | 117.00K |
| Cost of Revenue | 10.26M | 13.33M | 14.52M | 16.09M | 12.89M |
| Gross Profit | -10.26M | -13.33M | -14.52M | -16.03M | -12.77M |
| SG&A Expenses | 7.22M | 7.88M | 8.56M | 9.03M | 7.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.48M | 21.21M | 23.08M | 25.12M | 20.49M |
| Operating Income | -17.48M | -21.21M | -23.08M | -25.05M | -20.37M |
| Income Before Tax | 3.76M | -45.50M | -23.52M | -19.69M | -19.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.76M | -45.50M | -23.52M | -19.69M | -19.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.76M | -45.50M | -23.52M | -19.69M | -19.38M |
| EBIT | -17.48M | -21.21M | -23.08M | -25.05M | -20.37M |
| EBITDA | -17.14M | -20.86M | -22.73M | -24.68M | -19.95M |
| EPS Basic | 0.06 | -0.87 | -0.61 | -0.51 | -0.65 |
| Normalized Basic EPS | 0.04 | -0.55 | -0.38 | -0.32 | -0.40 |
| EPS Diluted | 0.06 | -0.87 | -0.61 | -0.51 | -0.65 |
| Normalized Diluted EPS | 0.04 | -0.55 | -0.38 | -0.32 | -0.40 |
| Average Basic Shares Outstanding | 62.03M | 52.17M | 38.83M | 38.61M | 29.99M |
| Average Diluted Shares Outstanding | 62.03M | 52.17M | 38.83M | 38.61M | 29.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |